Education
About Us
Working with TipRanks
Follow Us
Iterum Therapeutics Plc (ITRM)
NASDAQ:ITRM
ITRM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.81 - $3.02
Previous CloseN/A
Volume220.96K
Average Volume (3M)279.91K
Market Cap
$39.08M
Enterprise Value$68.71M
Total Cash (Recent Filing)-$25.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.12
Next Earnings
May 09, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding34,581,406
10 Day Avg. Volume303,925
30 Day Avg. Volume279,909
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-270.52
Enterprise Value/Ebitda-3.68
Forecast
1Y Price Target
$10.00Price Target Upside792.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Iterum Therapeutics News
PremiumCompany Announcements
Iterum Therapeutics Appoints New Board Members
PremiumCompany Announcements
Iterum Therapeutics Highlights FDA Approval and Financial Progress
PremiumCompany Announcements
Iterum Therapeutics Highlights FDA Approval and Market Potential
---
Bulls Say, Bears Say
Bulls Say
Market OpportunityThe addressable market for ORLYNVAH is approximately 40 million prescriptions per year, which represents a significant commercial opportunity.
Regulatory ApprovalORLYNVAH is the first oral penem approved in the US for uncomplicated urinary tract infections with a favorable label and marketing exclusivity extended to 10 years.
Strategic InitiativesIterum is evaluating potential opportunities to partner, license, or sell ORLYNVAH to maximize shareholder value, indicating potential upside in ITRM shares.
Bears Say
Market ChallengesFeedback from ID Week indicated excitement for a new oral option for uUTI patients, especially for higher-risk populations with limited or no alternative treatment options.
Market CompetitionThe FDA approved oral sulopenem, brand name ORLYNVAH, for the treatment of uncomplicated urinary tract infections in adult women with limited or no alternative oral antibiotic treatment.
---
Ownership Overview
8.33% Insiders
0.04% Mutual Funds
1.81% Other Institutional Investors
89.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ITRM FAQ
What was Iterum Therapeutics Plc’s price range in the past 12 months?
Iterum Therapeutics Plc lowest stock price was $0.81 and its highest was $3.02 in the past 12 months.
What is Iterum Therapeutics Plc’s market cap?
Iterum Therapeutics Plc’s market cap is $39.08M.
When is Iterum Therapeutics Plc’s upcoming earnings report date?
Iterum Therapeutics Plc’s upcoming earnings report date is May 09, 2025 which is in 22 days.
How were Iterum Therapeutics Plc’s earnings last quarter?
Iterum Therapeutics Plc released its earnings results on Feb 07, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.05.
Is Iterum Therapeutics Plc overvalued?
According to Wall Street analysts Iterum Therapeutics Plc’s price is currently Undervalued.
Does Iterum Therapeutics Plc pay dividends?
Iterum Therapeutics Plc does not currently pay dividends.
What is Iterum Therapeutics Plc’s EPS estimate?
Iterum Therapeutics Plc’s EPS estimate is -0.15.
How many shares outstanding does Iterum Therapeutics Plc have?
Iterum Therapeutics Plc has 34,581,406 shares outstanding.
What happened to Iterum Therapeutics Plc’s price movement after its last earnings report?
Iterum Therapeutics Plc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went down -4.027%.
Which hedge fund is a major shareholder of Iterum Therapeutics Plc?
Currently, no hedge funds are holding shares in ITRM
---
Iterum Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (792.86% Upside)
$10.00 (792.86% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.66%
12-Months-Change
Fundamentals
Return on Equity
607.06%
Trailing 12-Months
Asset Growth
69.83%
Trailing 12-Months
Company Description
Iterum Therapeutics Plc
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
---
ITRM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents significant achievements, particularly the FDA approval of ORLYNVAH and its market potential, coupled with improved financial performance. However, the uncertainty in strategic partnerships and financial obligations create notable challenges.Read More>---
ITRM Stock 12 Month Forecast
Average Price Target
$10.00
▲(792.86% Upside)
Technical Analysis
Fortress Biotech
―
Outlook Therapeutics
―
Spero Therapeutics
―
X4 Pharmaceuticals
―
Repare Therapeutics
―
Best Analysts Covering ITRM
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-11.21%
reiterated a buy rating 7 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -11.21% per trade.
---